HOME >> BIOLOGY >> NEWS
Nature's own medicine for vision loss: Inhibitor of angiogenesis found by biologists at The Scripps Research Institute

A potentially potent inhibitor of angiogenesis, the process whereby new blood vessels are formed from existing ones, can be found in one of the very molecules involved in the same process. This finding, made by two scientists from The Scripps Research Institute (TSRI), may lead to new therapies, as abnormal angiogenesis is the leading cause of vision loss in the United States.

In the current issue of the journal Proceedings of the National Academy of Sciences, two reports by collaborating authors from TSRI describe the antiangiogenesis activity of a fragment of the human protein tryptophanyl-tRNA synthetase (TrpRS). The reports are authored by Paul Schimmel, Ph.D., Ernest and Jean Hahn Professor, Chair of Molecular Biology and Chemistry, and member of The Skaggs Institute for Chemical Biology and Martin Friedlander, M.D., Ph.D., Associate Professor in the Department of Cell Biology and Chief of the Retina Service in the Division of Ophthalmology, Department of Surgery at Scripps Clinic.

"There are many potential applications [for TrpRS], ranging from blindness to cancer, that we want to pursue," says Schimmel.

Angiogenesis is a natural biological process that can sometimes go awry. Abnormal angiogenesis is the cause of age-related macular degeneration (ARMD) and diabetic retinopathy, diseases that afflict tens of millions of Americans and cause catastrophic vision loss in many.

Both of these eye diseases are characterized by the development of abnormal blood vessel growth in the eye. In the case of ARMD, new blood vessels grow under the retina. In diabetic retinopathy, abnormal vessels grow on top of the retina. The effect is much the same; the vessels interfere with normal structures or the transmission of light to the back of the eye, impeding vision. There is currently no effective treatment for the vast majority of these patients.

There are several antiangiogenic compounds in clinical trials. But TrpRS, says Friedlande
'"/>

Contact: Robin B. Goldsmith
rgoldsmi@scripps.edu
858-784-8134
Scripps Research Institute
2-Jan-2002


Page: 1 2 3

Related biology news :

1. Natures ambush: pregnancy more likely from single unprotected intercourse than believed
2. Researchers discover structure of Natures circuit breaker
3. Natures own antidote to cocaine
4. Natures chemical weapons save lives
5. Natures path leads scientists to new antibiotic strategy
6. Worlds Leading Echinacea Researchers To Examine Latest Scientific Findings On "Natures Gentle Antibiotic"
7. Natures Sugar High
8. Photosynthetic Harvest Inc. Harnesses The Power Of Natures Chemical Factories By "Milking" Green Plants For Valuable Natural Products
9. Probing the surface of white blood cells to enhance immune system medicine
10. From science fiction to reality: Nanomedicine brings fresh hope to the medical world
11. Annals of internal medicine tip sheet, July 20, 2004

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/6/2020)... ... February 06, 2020 , ... ... complex interventional medical device and pharmaceutical trials, announced that Ms. Dorothy Abel ... established role, Dorothy oversees the development and execution of regulatory plans designed ...
(Date:2/5/2020)... ... 2020 , ... LabKey has released Sample Manager, sample ... processing within laboratories. , Built with input from a Product Advisory Council ... Sample Manager has been designed with an intuitive user interface providing a gateway ...
(Date:1/29/2020)... , ... January 29, 2020 , ... ... the new Analytics and Data Sciences practice, providing consulting services for strategy, research ... was announced by Mike Townley, co-founder and Managing Partner of CREO, an innovative ...
Breaking Biology News(10 mins):
(Date:1/22/2020)... ... January 21, 2020 , ... Microbial Discovery Group LLC (MDG) ... Industrial and Institutional (I&I) Account Manager. Darrell will focus on servicing MDG’s partners ... over 30 years of sales experience working across multiple different market sectors such ...
(Date:1/10/2020)... ... January 09, 2020 , ... A new report from ... the vendor qualification process, a critical element of clinical trial set up and ... the vendor qualification process creates delays in initiation in 7% of clinical trials ...
(Date:1/8/2020)... ... January 08, 2020 , ... Anomet ... achieve specific properties for use in harsh environments inside or outside of the ... to three metals or alloys to achieve specific properties such as corrosion-resistance, biocompatibility, ...
(Date:1/7/2020)... ... , ... Vuja De Sciences (“Vuja De”), a biotechnology startup dedicated to developing ... Chand Khanna, DVM, PhD, DACVIM (Onc), and Dr. Lee Helman, MD, to its Board ... to welcome Chand and Lee as new directors. They will be of great help ...
Breaking Biology Technology:
Cached News: